EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
The Halol facility was placed under Import Alert by USFDA.
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
EC grants conditional marketing authorization based on the EFFISAYIL trial
This one-of-a-kind ophthalmic subspecialty division is focused on the treatment of the eye condition glaucoma
The approval follows the positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in October 2022
The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha
Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer
Subscribe To Our Newsletter & Stay Updated
